Thera-SAbDab

BIFIKAFUSP

> Structural Summary

Therapeutic	Bifikafusp
Target	FN extra domain B
Heavy Chain	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS
Light Chain	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb Fusion
Isotype	E
Highest Clinical Trial (August '23)	Phase-III
Estimated Status (August '23)	Active
Recorded Developmental Technology	na
INN Year Proposed	2010
INN Year Recommended	2011
Companies Involved	Philogen
Conditions Approved	na
Conditions Active	Non-small cell lung cancer%3BDiffuse large B-cell lymphoma%3B%5BWith onfekafusp%5D Malignant melanoma%3B%5BWith onfekafusp%5D Basal cell cancer%3B%5BWith onfekafusp%5D Squamous cell cancer%3B%5BWith onfekafusp%5D Solid tumours
Conditions Discontinued	Malignant melanoma%3BRenal cell carcinoma%3BSolid tumours%3BAtherosclerosis%3BHead and neck cancer%3BPancreatic cancer
Notes	Radretumab%2BBifikafusp%2BOnfekafusp have identical V domains

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy